Efficacy & Safety of Clindamycin and Tretinoin in Acne

• Status: Unknown status
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is ascertain the efficacy and safety of Clindamycin

Phosphate 1.2% and Tretinoin 0.025% in the treatment of Acne and Post

Inflammatory Hyperpigmentation in patients with skin of color.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Callender Center for Clinical Research
• Collaborator: Society Hill Dermatology
• Treatments: Clindamycin; Clindamycin palmitate; Clindamycin phosphate; Tretinoin

Criteria

Inclusion Criteria:

• Mild to moderate facial acne and mild to moderate post-inflammatory hyperpigmentation

• Photo skin types IV - VI

• Ages 12 and older

• Both sexes

• Two week washout period for topical anti-acne medications, medicated cosmetics,and bleaching products

• Thirty day washout period for oral corticosteroids, oral antibiotics,and oral contraceptives

Exclusion Criteria:

• Seborrheic dermatitis

• PIH of solely dermal origin

• Acne vulfaris known to be resistant to oral antibiotics

• Use of erythromycin-containing products

• Use of neuromuscular blocking agents

• Pregnancy, breastfeeding, a positive pregnancy test in the office, or plans to become pregnant. Women of childbearing age must use reliable forms of contraception (e.g., abstinence, oral contraceptives, or spermicide and condoms).